AR085711A1 - Compuesto de heteroaril oximetilen arilo sustituido, composicion farmaceutica y combinacion que lo comprenden y su uso para la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, cancer, una enfermedad inflamatoria y/o un trastorno alergico y una enfermedad asociada con la activacion inapropiada de las celulas cebadas - Google Patents
Compuesto de heteroaril oximetilen arilo sustituido, composicion farmaceutica y combinacion que lo comprenden y su uso para la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, cancer, una enfermedad inflamatoria y/o un trastorno alergico y una enfermedad asociada con la activacion inapropiada de las celulas cebadasInfo
- Publication number
- AR085711A1 AR085711A1 ARP120100750A ARP120100750A AR085711A1 AR 085711 A1 AR085711 A1 AR 085711A1 AR P120100750 A ARP120100750 A AR P120100750A AR P120100750 A ARP120100750 A AR P120100750A AR 085711 A1 AR085711 A1 AR 085711A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- alkyl
- cancer
- manufacture
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de heteroaril oximetilén arilo sustituido de la fórmula (1) en la que: X es CR¹ o N; Y es CH, C o N; R¹ es hidrógeno, alcoxi C₁₋₆ o alquilo C₁₋₆; R² es hidrógeno, alcoxi C₁₋₆, halo, -C(O)alquilo C₁₋₆, CN, halo-alquilo C₁₋₆ o C(O)NR⁴R⁵; R³ es hidrógeno o alcoxi C₁₋₆; R⁴ es hidrógeno o alquilo C₁₋₆; R⁵ es hidrógeno o alquilo C₁₋₆; y m y n son números enteros seleccionado cada uno independientemente de 1 y 2; o una de sus sales. Una composición farmacéutica que comprende el compuesto de la fórmula (1) o una de las sales farmacéuticamente aceptables y uno o más vehículos, diluyentes o excipientes farmacéuticamente aceptables y una combinación que comprende dicho compuesto o una de sus sales farmacéuticamente aceptables junto con uno o más de otros agentes terapéuticamente activos. Uso del compuesto o una de sus sales farmacéuticamente aceptables para la fabricación de un medicamento para el tratamiento de una enfermedad autoinmune, tal como urticaria idiopática crónica con y sin auto-anticuerpos o lupus discoide (cutáneo); del cáncer; de una enfermedad inflamatoria y/o trastorno alérgico y de una enfermedad asociada con la activación inapropiada de las células cebadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1104153.0A GB201104153D0 (en) | 2011-03-11 | 2011-03-11 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085711A1 true AR085711A1 (es) | 2013-10-23 |
Family
ID=43980841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100750A AR085711A1 (es) | 2011-03-11 | 2012-03-08 | Compuesto de heteroaril oximetilen arilo sustituido, composicion farmaceutica y combinacion que lo comprenden y su uso para la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, cancer, una enfermedad inflamatoria y/o un trastorno alergico y una enfermedad asociada con la activacion inapropiada de las celulas cebadas |
Country Status (41)
| Country | Link |
|---|---|
| US (4) | US8993560B2 (es) |
| EP (2) | EP2683709B1 (es) |
| JP (1) | JP5902206B2 (es) |
| KR (1) | KR101564007B1 (es) |
| CN (1) | CN103502239B (es) |
| AR (1) | AR085711A1 (es) |
| AU (1) | AU2012228439C1 (es) |
| BR (1) | BR112013022784A2 (es) |
| CA (1) | CA2828518C (es) |
| CL (1) | CL2013002602A1 (es) |
| CO (1) | CO6791612A2 (es) |
| CR (1) | CR20130459A (es) |
| CY (2) | CY1116569T1 (es) |
| DK (2) | DK2937344T3 (es) |
| DO (1) | DOP2013000207A (es) |
| EA (1) | EA022437B1 (es) |
| ES (2) | ES2641483T3 (es) |
| GB (1) | GB201104153D0 (es) |
| HK (2) | HK1192887A1 (es) |
| HR (2) | HRP20150752T1 (es) |
| HU (2) | HUE035443T2 (es) |
| IL (1) | IL227873A (es) |
| JO (1) | JO3072B1 (es) |
| LT (1) | LT2937344T (es) |
| MA (1) | MA35030B1 (es) |
| ME (2) | ME02167B (es) |
| MX (1) | MX339123B (es) |
| MY (1) | MY169314A (es) |
| NO (1) | NO2937344T3 (es) |
| PE (1) | PE20140998A1 (es) |
| PL (2) | PL2683709T3 (es) |
| PT (2) | PT2937344T (es) |
| RS (2) | RS56719B1 (es) |
| SG (1) | SG193015A1 (es) |
| SI (2) | SI2937344T1 (es) |
| SM (1) | SMT201500188B (es) |
| TW (1) | TWI527806B (es) |
| UA (1) | UA109807C2 (es) |
| UY (1) | UY33942A (es) |
| WO (1) | WO2012123311A1 (es) |
| ZA (1) | ZA201306554B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014081616A1 (en) * | 2012-11-21 | 2014-05-30 | Merck Sharp & Dohme Corp. | Preparation of precursors for leukotriene antagonists |
| WO2017017571A1 (en) | 2015-07-24 | 2017-02-02 | Glaxo Group Limited | Treatment for vitiligo |
| JP2020537678A (ja) | 2017-10-19 | 2020-12-24 | バイエル・アニマル・ヘルス・ゲーエムベーハー | 動物における疾患の治療および予防のための縮合ヘテロ芳香族ピロリドンの使用 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US20220227717A1 (en) * | 2019-04-23 | 2022-07-21 | The Clevland clinic Foundatio | Allosteric activators of the alpha1a-adrenergic receptor |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN113340965B (zh) * | 2020-03-03 | 2022-12-16 | 北京中医药大学 | 一种用于检测扑尔敏用途的人工智能生物传感器检测方法 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1201114A (en) | 1980-02-15 | 1986-02-25 | Gordon H. Phillipps | Androstane carbothioates |
| AU570439B2 (en) | 1983-03-28 | 1988-03-17 | Compression Labs, Inc. | A combined intraframe and interframe transform coding system |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| FR2665159B1 (fr) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| EP0633776B1 (en) | 1992-04-02 | 2001-05-09 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| IL108630A0 (en) * | 1993-02-18 | 1994-05-30 | Fmc Corp | Insecticidal substituted 2,4-diaminoquinazolines |
| US5426196A (en) | 1993-12-22 | 1995-06-20 | Glaxo Inc. | Synthesis of diaryl methanes |
| CA2192668A1 (en) | 1994-06-15 | 1995-12-21 | Harold Francis Hodson | Amidino sulfone derivatives for use as inos inhibitors claims |
| US6017919A (en) | 1996-02-06 | 2000-01-25 | Japan Tobacco Inc. | Compounds and pharmaceutical use thereof |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| AR015649A1 (es) | 1997-05-07 | 2001-05-16 | Univ Pittsburgh | Inhibidores de isoprenil-transferasas proteicas, composiciones que los comprenden y el uso de los mismos para la fabricacion de un medicamento |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
| WO1999018096A1 (en) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO1999031073A1 (fr) | 1997-12-15 | 1999-06-24 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives de pyrimidine-5-carboxamide |
| ATE271555T1 (de) | 1998-01-14 | 2004-08-15 | Uab Research Foundation | Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| ES2224628T3 (es) | 1998-03-14 | 2005-03-01 | Altana Pharma Ag | Inhibidores de pde iii/iv a base de ftalazinonas. |
| WO1999061410A1 (en) | 1998-05-12 | 1999-12-02 | American Home Products Corporation | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| AU2871900A (en) | 1999-02-04 | 2000-08-25 | Millennium Pharmaceuticals, Inc. | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
| CA2371273A1 (en) | 1999-05-04 | 2000-11-09 | Andrew Fensome | Tetracyclic progesterone receptor modulator compounds and methods |
| AU4537400A (en) | 1999-05-12 | 2000-12-05 | Neurosearch A/S | Ion channel modulating agents |
| AU5780800A (en) | 1999-06-29 | 2001-01-31 | Uab Research Foundation, The | Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| EP1273287A1 (en) | 2000-04-04 | 2003-01-08 | Shionogi & Co., Ltd. | Oily compositions containing highly fat-soluble drugs |
| AU2001244610A1 (en) | 2000-04-05 | 2001-10-23 | Shionogi And Co., Ltd. | Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof |
| BRPI0113042B8 (pt) | 2000-08-05 | 2021-05-25 | Glaxo Group Ltd | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato |
| BR0114323A (pt) | 2000-09-29 | 2003-07-01 | Glaxo Group Ltd | Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| BR0209271A (pt) | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto |
| US20040248867A1 (en) | 2001-06-12 | 2004-12-09 | Keith Biggadike | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
| EP1578898A2 (en) | 2001-07-13 | 2005-09-28 | Virtual Drug Development, Inc. | Nad synthetase inhibitors and uses thereof |
| USRE44874E1 (en) | 2001-09-14 | 2014-04-29 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| WO2003050174A1 (en) | 2001-12-11 | 2003-06-19 | Rhodia Chimie | Catalytic pgm mixture for hydrosilylation |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
| CA2472746A1 (en) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| EP1467730A4 (en) | 2002-01-22 | 2010-03-10 | Univ California | Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| CN1633296A (zh) | 2002-03-26 | 2005-06-29 | 贝林格尔·英格海姆药物公司 | 糖皮质素模拟物、其制备方法、药物组合物及其用途 |
| JP2005521717A (ja) | 2002-03-26 | 2005-07-21 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| CA2481320A1 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| AU2003222841A1 (en) | 2002-04-25 | 2003-11-10 | Glaxo Group Limited | Phenethanolamine derivatives |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| EP1521733B1 (en) | 2002-07-08 | 2014-08-20 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| JP2006504678A (ja) | 2002-08-21 | 2006-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| ES2331119T3 (es) | 2002-09-16 | 2009-12-22 | Glaxo Group Limited | Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa. |
| AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| AU2003301433A1 (en) | 2002-10-16 | 2004-05-04 | Millennium Pharmaceuticals, Inc. | Spleen tyrosine kinase catalytic domain:crystal structure and binding pockets thereof |
| ES2291733T3 (es) | 2002-10-22 | 2008-03-01 | Glaxo Group Limited | Compuestos de ariletanolamina medicinales. |
| SI1556342T1 (sl) | 2002-10-28 | 2008-08-31 | Glaxo Group Ltd | Fenetanolaminski derivat za zdravljenje respiratornih bolezni |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| CA2509413C (en) | 2002-12-20 | 2012-05-01 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| US7470807B2 (en) * | 2003-08-14 | 2008-12-30 | Asahi Kasei Pharma Corporation | Substituted arylalkanoic acid derivatives and use thereof |
| CN1901958B (zh) | 2003-11-03 | 2011-03-09 | 葛兰素集团有限公司 | 流体分配装置 |
| JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
| EP1737809B1 (en) | 2004-02-27 | 2013-09-18 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| US20050250820A1 (en) | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
| WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
| WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| ES2367515T3 (es) | 2004-10-19 | 2011-11-04 | F. Hoffmann-La Roche Ag | Derivados de quinolina. |
| US7579335B2 (en) | 2005-01-10 | 2009-08-25 | Glaxo Group Limited | Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
| US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
| MX2007009388A (es) | 2005-02-04 | 2007-09-25 | Senomyx Inc | Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles. |
| EP1869003B1 (en) | 2005-04-14 | 2013-05-15 | Glaxo Group Limited | Indazoles as glucocorticoid receptor ligands |
| GB0513297D0 (en) | 2005-06-29 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
| PE20070362A1 (es) * | 2005-07-15 | 2007-04-23 | Glaxo Group Ltd | COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk) |
| JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070104620A1 (en) | 2005-11-07 | 2007-05-10 | Bilal Zuberi | Catalytic Exhaust Device |
| GB0522880D0 (en) | 2005-11-09 | 2005-12-21 | Glaxo Group Ltd | Novel compounds |
| US7687526B2 (en) | 2006-09-07 | 2010-03-30 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| WO2008046216A1 (en) | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| LT2848610T (lt) | 2006-11-15 | 2017-11-10 | Ym Biosciences Australia Pty Ltd | Kinazės aktyvumo inhibitoriai |
| JP2010513519A (ja) | 2006-12-22 | 2010-04-30 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | キナーゼインヒビター活性を有するある種のピラゾリン誘導体 |
| TW201006090A (en) | 2008-07-16 | 2010-02-01 | Chien-Chiang Chan | Applied structure of energy storage device |
| EP2321334A1 (en) | 2008-08-05 | 2011-05-18 | Nicox S.A. | New no releasing steroids derivatives |
| US8604049B2 (en) | 2008-08-05 | 2013-12-10 | Boehringer Ingelheim International Gmbh | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
| GB0910691D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| JP2013510178A (ja) | 2009-11-06 | 2013-03-21 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ４アロステリック増強剤としてのアリールおよびヘテロアリールスルホン、組成物、および神経機能不全を治療する方法 |
-
2011
- 2011-03-11 GB GBGB1104153.0A patent/GB201104153D0/en not_active Ceased
-
2012
- 2012-03-08 MA MA36313A patent/MA35030B1/fr unknown
- 2012-03-08 PT PT151661097T patent/PT2937344T/pt unknown
- 2012-03-08 SI SI201231072T patent/SI2937344T1/sl unknown
- 2012-03-08 ES ES15166109.7T patent/ES2641483T3/es active Active
- 2012-03-08 UY UY0001033942A patent/UY33942A/es not_active Application Discontinuation
- 2012-03-08 JO JOP/2012/0050A patent/JO3072B1/ar active
- 2012-03-08 DK DK15166109.7T patent/DK2937344T3/en active
- 2012-03-08 RS RS20170962A patent/RS56719B1/sr unknown
- 2012-03-08 ME MEP-2015-102A patent/ME02167B/me unknown
- 2012-03-08 EA EA201391165A patent/EA022437B1/ru not_active IP Right Cessation
- 2012-03-08 CA CA2828518A patent/CA2828518C/en not_active Expired - Fee Related
- 2012-03-08 NO NO15166109A patent/NO2937344T3/no unknown
- 2012-03-08 HU HUE15166109A patent/HUE035443T2/en unknown
- 2012-03-08 DK DK12707342.7T patent/DK2683709T3/en active
- 2012-03-08 PL PL12707342T patent/PL2683709T3/pl unknown
- 2012-03-08 KR KR1020137026876A patent/KR101564007B1/ko active IP Right Grant
- 2012-03-08 PT PT127073427T patent/PT2683709E/pt unknown
- 2012-03-08 US US13/414,873 patent/US8993560B2/en not_active Expired - Fee Related
- 2012-03-08 SI SI201230253T patent/SI2683709T1/sl unknown
- 2012-03-08 MY MYPI2013701607A patent/MY169314A/en unknown
- 2012-03-08 PL PL15166109T patent/PL2937344T3/pl unknown
- 2012-03-08 SG SG2013065750A patent/SG193015A1/en unknown
- 2012-03-08 EP EP12707342.7A patent/EP2683709B1/en active Active
- 2012-03-08 US US14/004,388 patent/US20140005177A1/en not_active Abandoned
- 2012-03-08 AU AU2012228439A patent/AU2012228439C1/en not_active Ceased
- 2012-03-08 AR ARP120100750A patent/AR085711A1/es unknown
- 2012-03-08 MX MX2013010373A patent/MX339123B/es active IP Right Grant
- 2012-03-08 EP EP15166109.7A patent/EP2937344B1/en active Active
- 2012-03-08 HU HUE12707342A patent/HUE026541T2/en unknown
- 2012-03-08 ME MEP-2017-218A patent/ME02872B/me unknown
- 2012-03-08 RS RS20150449A patent/RS54120B1/en unknown
- 2012-03-08 CN CN201280022632.7A patent/CN103502239B/zh not_active Expired - Fee Related
- 2012-03-08 JP JP2013557086A patent/JP5902206B2/ja not_active Expired - Fee Related
- 2012-03-08 WO PCT/EP2012/053948 patent/WO2012123311A1/en active Application Filing
- 2012-03-08 PE PE2013002037A patent/PE20140998A1/es active IP Right Grant
- 2012-03-08 BR BR112013022784A patent/BR112013022784A2/pt not_active Application Discontinuation
- 2012-03-08 LT LTEP15166109.7T patent/LT2937344T/lt unknown
- 2012-03-08 ES ES12707342.7T patent/ES2541530T3/es active Active
- 2012-03-08 TW TW101107813A patent/TWI527806B/zh not_active IP Right Cessation
- 2012-08-03 UA UAA201310451A patent/UA109807C2/uk unknown
-
2013
- 2013-08-08 IL IL227873A patent/IL227873A/en active IP Right Grant
- 2013-08-20 CO CO13197322A patent/CO6791612A2/es active IP Right Grant
- 2013-08-30 ZA ZA2013/06554A patent/ZA201306554B/en unknown
- 2013-09-10 CL CL2013002602A patent/CL2013002602A1/es unknown
- 2013-09-11 CR CR20130459A patent/CR20130459A/es unknown
- 2013-09-11 DO DO2013000207A patent/DOP2013000207A/es unknown
-
2014
- 2014-06-24 HK HK14106105.3A patent/HK1192887A1/xx not_active IP Right Cessation
-
2015
- 2015-02-19 US US14/625,804 patent/US9447074B2/en active Active
- 2015-07-08 HR HRP20150752TT patent/HRP20150752T1/hr unknown
- 2015-07-24 CY CY20151100654T patent/CY1116569T1/el unknown
- 2015-08-05 SM SM201500188T patent/SMT201500188B/xx unknown
-
2016
- 2016-04-27 HK HK16104812.0A patent/HK1216751A1/zh not_active IP Right Cessation
- 2016-08-19 US US15/241,160 patent/US20160355505A1/en not_active Abandoned
-
2017
- 2017-10-27 HR HRP20171647TT patent/HRP20171647T1/hr unknown
- 2017-11-08 CY CY20171101175T patent/CY1119581T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085711A1 (es) | Compuesto de heteroaril oximetilen arilo sustituido, composicion farmaceutica y combinacion que lo comprenden y su uso para la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, cancer, una enfermedad inflamatoria y/o un trastorno alergico y una enfermedad asociada con la activacion inapropiada de las celulas cebadas | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| EA201891049A1 (ru) | Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2 | |
| CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
| ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| AR100006A1 (es) | Derivados de tubulisina | |
| CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
| CL2012003745A1 (es) | Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| AR095034A1 (es) | El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares | |
| EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
| EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
| EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
| EA202190167A1 (ru) | Замещенные фенилоксазолидиноны для антимикробной терапии | |
| DOP2014000114A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
| UY35209A (es) | Compuestos tricíclicos | |
| AR095858A1 (es) | COMBINACIONES DE LIGANDOS DE RECEPTORES ADRENÉRGICOS a-2 Y RECEPTORES SIGMA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |